Get started
Nkarta, Inc.Nkarta, Inc.Nkarta, Inc.

Nkarta, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

NKTX trade ideas

NKTX: A technical perspectiveNASDAQ:NKTX is a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. While highly speculative, the daily charts have presented a purchasing opportunity after a stock offering to raise capital. MACD and TTM Squeeze tend to be reversing, and selling pressure seems to slow. I expect price to bounce off of the critical support level around 8.47. A price below 8.47 justifies a premium valuation of the underlying. Short-term price action appears to be slightly bearish, but the conditions are right for a reversal. Biotechnology stocks tend to be highly volatile, make sure to manage your risk correctly before making a trade. My R:R ratio is around 5:1 with a SL at 8.08.
NASDAQ:NKTXLong
by babytrades_
NKTX | Oversold Healthcare Play | LONGNkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NASDAQ:NKTXLong
by DivergenceSeeker
NKTX LONG SET UPNKTX LONG SET UP Sector: Health Technology Industry: Biotechnology Employees: --- Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA. Top 10% Owner Trading Recent Week Filter Buy Transactions Ticker Owner Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4 NKTX RA CAPITAL MANAGEMENT, L.P. 10% Owner Jul 14 Buy 18.00 3,333,333 59,999,994 5,605,129 Jul 16 04:30 PM NKTX Florence Anthony A. Jr. 10% Owner Jul 14 Buy 18.00 666,666 11,999,988 2,902,115 Jul 16 05:00 PM NKTX MAKOWER JOSHUA 10% Owner Jul 14 Buy 18.00 666,666 11,999,988 2,902,115 Jul 16 05:00 PM NKTX BASKETT FOREST 10% Owner Jul 14 Buy 18.00 666,666 11,999,988 2,902,115 Jul 16 05:00 PM NKTX Makhzoumi Mohamad 10% Owner Jul 14 Buy 18.00 666,666 11,999,988 2,902,115 Jul 16 05:00 PM NKTX Sonsini Peter W. 10% Owner Jul 14 Buy 18.00 666,666 11,999,988 2,902,115 Jul 16 05:00 PM NKTX SANDELL SCOTT D 10% Owner Jul 14 Buy 18.00 666,666 11,999,988 2,902,115 Jul 16 05:00 PM NKTX New Enterprise Associates 15, 10% Owner Jul 14 Buy 18.00 666,666 11,999,988 2,902,115 Jul 16 05:00 PM NKTX Novo Holdings A/S 10% Owner Jul 14 Buy 18.00 555,555 9,999,990 2,793,865 Jul 16 04:41 PM
NASDAQ:NKTXLong
by MavRich_Trading